Posts

cliexa is a semifinalist in the AHRQ's Step-Up Challenge

cliexa is a semifinalist in the AHRQ's Step-Up Challenge

cliexa is one of 10 companies out of 50+ advancing to Phase 2 of the Agency for Healthcare Research and Quality (AHRQ)‘s Step-Up App Challenge with the “goal of developing an app that integrates standardized patient-reported outcomes (PRO) data into clinical care and research.”

For Phase 2 of the Step Up App Challenge, cliexa will design, develop, and demo our application using the FHIR technical specifications and PROMIS® resources for patient-reported outcomes with the hope to be selected as one of the three winners, who will get the opportunity to test their product in nine practice settings affiliated with MedStar Health in Washington, DC.

Read the blog announcing the 10 semifinalists from Director of the AHRQ, Gopal Khanna, M.B.A: //www.ahrq.gov/news/blog/ahrqviews/stepup-challenge-finalists.html

Check out our portfolio of patient-reported outcomes applications: cliexa Mobile

Digital health benefits

2018 has seen a significant boom in the application of technology in digital health innovation, which are poised to disrupt the healthcare industry. Innovations have included advances in mobile health (mHealth), health information technology (IT), as well as wearable and Internet-of-Things (IoT) devices.

cliexa has identified six specific areas of medicine already reaping the benefits of digital health innovation:

1. Rheumatology

Disease Activity Scoring (DAS) metrics remotely collected by cliexa from patients are used by physicians in their offices when assessing the severity of rheumatoid arthritis through a Q & A approach. cliexa empowers patients with the ability to communicate their patient-reported outcomes to their physicians at the touch of a finger, on their own mobile devices, providing physicians with instantly-scored clinically-validated assessments. The application of cliexa innovations in rheumatology drastically increases the efficiency and quality-of-care for both patients and their providers.

Check out the cliexa mobile platform for Rheumatoid Arthritis, cliexa-RA: //www.cliexa.com/cliexamobile/rheumatoid-arthritis/

2. Pain Management, Primary Care, & Integrative Medicine

Chronic pain, affecting over 10% of American adults, is a leading cause of opiate abuse. Managing and overcoming chronic pain is a complex obstacle for many healthcare providers. With the increased shift away from the prescribing of opioids in the treatment of chronic pain, cliexa enables providers to remotely monitors opioid-prescribed patients while empowering them to relay their patient-reported outcomes and track their mental health conditions in association with their chronic pain, while catering specifically towards the individual needs of each patient-provider relationship.

Check out the cliexa mobile platform for Pain Management, cliexa-EASE: //www.cliexa.com/cliexamobile/pain-management/

3. Behavioral Health & Addiction Treatment

Though struggles with addiction are becoming increasingly more prevalent in society, the present methods of addiction treatment are limited. Through innovations in health technologies, patients and providers are shifting towards new ways of treating addiction. The monitoring of patients in real-time is essential for positive treatment outcomes for both patients and their providers. By leveraging patient-reported data, patients adhere to their treatment plans and overcome addiction as a disease, rather than as a fault.

Check out the cliexa mobile platform for Behavioral Health, cliexa-SENSE: //www.cliexa.com/cliexamobile/behavioral-health/

4. Digestive Health

Through cliexa innovations, providers better manage chronic gastrointestinal diseases, such as inflammatory bowel disease or ulcerative colitis, using specifically-designed, highly-structured treatment plans that leverage disease activity scoring models taken from qualitative patient responses to assessments which quantify and track symptoms over long periods of time.

Check out the cliexa mobile platform for Digestive Health, cliexa-IBD: //www.cliexa.com/cliexamobile/inflammatory-bowel-disease/

5. Respiratory Care

cliexa enables providers to qualitatively track chronic diseases of the respiratory system, like chronic obstructive pulmonary disease (COPD), through remote patient-reported outcomes. The ability to structure individualized and specialized care leads to improved patient-provider experiences.

Check out the cliexa mobile platform for Respiratory Care, cliexa-COPD: //www.cliexa.com/cliexamobile/chronic-obstructive-pulmonary-disease/

6. Pediatric Care

cliexa health technology drives innovations in mental health resiliency in adolescents, a hot topic in today’s health community. cliexa’s clinically validated medical assessment applications, coupled with its mHealth prevention services, help providers identify and reduce risk behaviors in adolescents and young adults. cliexa’s mobile patient-engagement applications equip providers with the tools adolescents use to overcome anxiety and depression, increasing the overall quality-of-care for both patients and providers.

Check out the cliexa mobile platform for Pediatric Care, cliexa-OPTIONS: //www.cliexa.com/cliexamobile/adolescent-resiliency/

cliexaRA Press Release

cliexa® partners with the Colorado Arthritis Center to identify how screening and monitoring of Rheumatoid Arthritis patients through a customized electronic platform, cliexa-RA, impacts clinical efficiency.

See the full press release from PR.com: //www.pr.com/press-release/765307

Download the Case Study here: //www.cliexa.com/cliexa-ra-case-study/

Learn more about cliexa-RA: //www.cliexa.com/cliexamobile/rheumatoid-arthritis/

cliexa-Protocols, web-based disease management system is a member of cliexaTM family of products which is a data and algorithm hub. It provides decision support to physicians and other healthcare providers during the treatment process and optimizes treatment methods based on evidence-based knowledge and data.

cliexa-Protocols has started as a pilot program, developed and evolved in early 2014. It was recognized and initiated letter of intents by multiple healthcare provider firms as well as specialty pharma focusing on Hyponatremia and Hep C treatments.

In December 2013, CN4CE Inc. has submitted a 513(g) application for cliexa-Protocols. After reviewed by FDA, FDA confirmed that cliexa-Protocols Disease Management System is a medical device as defined in section 201(h) of the Act.

On May 10, 2016, cliexa-Protocols has received a confirmation from FDA for 513(g) application as cliexa-Protocols will not be enforced any regulatory requirements under applicable provisions of the Section 513(g) Act, including premarket notification, and its implementing regulations, in accordance with the Mobile Medical Applications Guidance.